ML22774
In the current study it is examined whether patients with good risk factors (age <75 years,
total serum bilirubin < 1,5xULN, no history of cardiovascular diseases) treated with
gemcitabine and erlotinib who developed skin rash of any grade during the first 4 weeks of
treatment have a comparable outcome as patients who receive FOLFIRINOX.
Jul 31,2012
All
18 Years
75 Years
18 Years
75 Years
150